Subscribe To
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Coherus announces toripalimab data at 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics
— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 ...
October 14, 2023, 4:30 pm
Mid-october 2023 watchlist: leading ancillary cannabis stocks
The cannabis industry's landscape is still changing at an incredibly fast rate as we approach mid-October 2023. The ancillary business has become a ho...
October 14, 2023, 3:00 pm
Middle east unrest shakes financial markets; safe havens gain ground
The abrupt escalation in conflicts in the Middle East significantly influenced the global financial mar...
October 14, 2023, 9:40 am
Kaiser aluminum: investor pessimism has left an appealing 4.6% dividend yield on cost
Revenues are expected to decline by 7% in 2023 due to customer destocking and weak demand but will start slowly recovering in 2024. Profit margins hav...
October 14, 2023, 8:04 am
Crude oil price forecast – crude oil markets rally on friday
The crude oil market has rallied significantly during the trading session on Friday, as we continue to ...
October 13, 2023, 3:47 pm